Fig. 6: 4HNE suppresses tumor growth by inducing ferroptosis in vivo.
From: A noncanonical function of EIF4E limits ALDH1B1 activity and increases susceptibility to ferroptosis
a Athymic nude mice were injected subcutaneously with HT-1080 cells for 7 days and then given intratumoral treatment with 4HNE (5 mg/kg, once every other day) in the absence or presence of ZVAD-FMK (5 mg/kg, once every other day) or liproxstatin-1 (5 mg/kg, once every other day) at day 7 for 2 weeks. Tumor volumes were calculated weekly (n = 6 mice/group; two-way ANOVA with Tukey’s multiple comparisons test; data were presented as mean ± SD). b Photographs of isolated tumors on day 14 after treatment. c–h The levels of PTGS2 mRNA (c), serum HMGB1 (d), and caspase-3 activity in isolated tumors (e); body weight (f), serum ALT (g), and serum BUN (h) at day 14 after treatment were assayed (n = 6 mice/group; one-way ANOVA with Tukey’s multiple comparisons test; data were presented as mean ± SD). i Athymic nude mice were injected subcutaneously with indicated HT-1080 cells for 7 days and then given intratumoral treatment with 4HNE (5 mg/kg, once every other day) at day 7 for 2 weeks. Tumor volumes were calculated weekly (n = 6 mice/group; two-way ANOVA with Tukey’s multiple comparisons test; data are presented as mean ± SD). j, k The levels of PTGS2 mRNA in tumor (j) and serum HMGB1 (k) at day 14 after treatment were assayed (n = 6 mice/group; one-way ANOVA with Tukey’s multiple comparisons test; data were presented as mean ± SD).
